First Patient Dosed in Phase 2b Study of GlyphAllo for Patients With Major Depressive Disorder, With or Without Anxious Stress

First Patient Dosed in Phase 2b Study of GlyphAllo for Patients With Major Depressive Disorder, With or Without Anxious Stress

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress